BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 14655194)

  • 41. 25-hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy.
    Coen G; Mantella D; Manni M; Balducci A; Nofroni I; Sardella D; Ballanti P; Bonucci E
    Kidney Int; 2005 Oct; 68(4):1840-8. PubMed ID: 16164662
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
    Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of high dialysate calcium concentration on bone remodelling, serum biochemistry, and parathyroid hormone in patients with renal osteodystrophy.
    Drüeke T; Bordier PJ; Man NK; Jungers P; Marie P
    Kidney Int; 1977 Apr; 11(4):267-74. PubMed ID: 857076
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
    Block GA; Bushinsky DA; Cheng S; Cunningham J; Dehmel B; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Moe SM; Patel UD; Silver J; Sun Y; Wang H; Chertow GM
    JAMA; 2017 Jan; 317(2):156-164. PubMed ID: 28097356
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evidence for both abnormal set point of PTH stimulation by calcium and adaptation to serum calcium in hemodialysis patients with hyperparathyroidism.
    Rodriguez M; Caravaca F; Fernandez E; Borrego MJ; Lorenzo V; Cubero J; Martin-Malo A; Betriu A; Rodriguez AP; Felsenfeld AJ
    J Bone Miner Res; 1997 Mar; 12(3):347-55. PubMed ID: 9076577
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Long-term treatment with large doses of alphacalicidol in secondary hyperparathyroidism of patients dialyzed for end stage renal failure].
    Matuszkiewicz-Rowińska J; Niemczyk S; Pacocha E; Puka J; Switalski M; Bogdańska-Straszyńska B; Ostrowski K
    Pol Arch Med Wewn; 1996 Jul; 96(1):15-22. PubMed ID: 8966141
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget's disease of bone and hypercalcaemia of malignancy.
    Fraser WD; Logue FC; Gallacher SJ; O'Reilly DS; Beastall GH; Ralston SH; Boyle IT
    Bone Miner; 1991 Feb; 12(2):113-21. PubMed ID: 1849762
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Elevated FGF23 levels are associated with impaired calcium-mediated suppression of PTH in ESRD.
    Wetmore JB; Santos PW; Mahnken JD; Krebill R; Menard R; Gutta H; Quarles LD
    J Clin Endocrinol Metab; 2011 Jan; 96(1):E57-64. PubMed ID: 20943782
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dynamic follow-up of the intact parathormone levels in hemodialysis patients treated with Rocaltrol and calcium.
    Dimitrakov D; Koumtchev E; Dimitrova R; Stavrev P
    Folia Med (Plovdiv); 1998; 40(4):48-53. PubMed ID: 10371800
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease.
    Quarles LD; Sherrard DJ; Adler S; Rosansky SJ; McCary LC; Liu W; Turner SA; Bushinsky DA
    J Am Soc Nephrol; 2003 Mar; 14(3):575-83. PubMed ID: 12595492
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of a low calcium dialysate on parathyroid hormone secretion in diabetic patients on maintenance hemodialysis.
    Holgado R; Haire H; Ross D; Sprague S; Pahl M; Jara A; Martin-Malo A; Rodriguez M; Almaden Y; Felsenfeld AJ
    J Bone Miner Res; 2000 May; 15(5):927-35. PubMed ID: 10804023
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD.
    Quarles LD; Yohay DA; Carroll BA; Spritzer CE; Minda SA; Bartholomay D; Lobaugh BA
    Kidney Int; 1994 Jun; 45(6):1710-21. PubMed ID: 7933819
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
    Brandi L; Daugaard H; Nielsen PK; Jensen LT; Egsmose C; Olgaard K
    Nephron; 1996; 74(1):89-103. PubMed ID: 8883025
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Non-suppressible parathyroid hormone secretion is related to gland size in uremic secondary hyperparathyroidism.
    Indridason OS; Heath H; Khosla S; Yohay DA; Quarles LD
    Kidney Int; 1996 Nov; 50(5):1663-71. PubMed ID: 8914034
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The calcitonin-calcium relation curve and calcitonin secretory parameters in renal patients with variable degrees of renal function.
    Messa P; Mioni G; Turrin D; Guerra UP
    Nephrol Dial Transplant; 1995 Dec; 10(12):2259-65. PubMed ID: 8808222
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.
    Lindberg JS; Moe SM; Goodman WG; Coburn JW; Sprague SM; Liu W; Blaisdell PW; Brenner RM; Turner SA; Martin KJ
    Kidney Int; 2003 Jan; 63(1):248-54. PubMed ID: 12472790
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hypercalcemia during pulse vitamin D3 therapy in CAPD patients treated with low calcium dialysate: the role of the decreasing serum parathyroid hormone level.
    Chagnac A; Ori Y; Weinstein T; Zevin D; Korzets A; Hirsh J; Edelstein S; Gafter U
    J Am Soc Nephrol; 1997 Oct; 8(10):1579-86. PubMed ID: 9335387
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dynamic tests of parathyroid hormone secretion using hemodialysis and calcium infusion cannot be compared.
    Moysés RM; Pereira RC; Machado dos Reis L; Sabbaga E; Jorgetti V
    Kidney Int; 1999 Aug; 56(2):659-65. PubMed ID: 10432406
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Measurement of PTH fragments for assessment of renal bone disease in hemodialysis patients.
    Fehr T; Garzoni D; Staub T; Binet I; Wüthrich RP
    Kidney Blood Press Res; 2006; 29(3):175-81. PubMed ID: 16931896
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The set point of parathyroid hormone stimulation by calcium is normal in progressive renal failure.
    Cardinal H; Brossard JH; Roy L; Lepage R; Rousseau L; D'Amour P
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3839-44. PubMed ID: 9814455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.